Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 94.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,507 shares of the biopharmaceutical company's stock after selling 585,930 shares during the quarter. Bank of America Corp DE's holdings in Xencor were worth $770,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Barclays PLC increased its holdings in Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock worth $3,128,000 after purchasing an additional 78,066 shares during the period. KBC Group NV lifted its holdings in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 813 shares during the period. Yousif Capital Management LLC grew its position in shares of Xencor by 10.2% during the 4th quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company's stock worth $482,000 after buying an additional 1,944 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Xencor by 12.7% during the fourth quarter. State of Alaska Department of Revenue now owns 39,773 shares of the biopharmaceutical company's stock valued at $913,000 after buying an additional 4,487 shares during the period. Finally, Louisiana State Employees Retirement System increased its stake in shares of Xencor by 13.0% during the fourth quarter. Louisiana State Employees Retirement System now owns 33,800 shares of the biopharmaceutical company's stock valued at $777,000 after buying an additional 3,900 shares during the period.

Xencor Stock Down 0.9%

Shares of Xencor stock traded down $0.09 during trading on Thursday, reaching $9.43. The company's stock had a trading volume of 451,862 shares, compared to its average volume of 666,413. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The company has a 50-day simple moving average of $9.01 and a two-hundred day simple moving average of $15.41. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market cap of $671.14 million, a price-to-earnings ratio of -2.95 and a beta of 0.87.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. During the same period in the prior year, the business posted ($1.11) EPS. Xencor's revenue was up 104.6% compared to the same quarter last year. As a group, equities analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on XNCR shares. Wells Fargo & Company dropped their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Wedbush reissued an "outperform" rating and set a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. William Blair assumed coverage on shares of Xencor in a research note on Monday, April 21st. They issued an "outperform" rating for the company. Barclays dropped their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.50.

Insider Buying and Selling

In other news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.76% of the stock is owned by company insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.